Among biomarkers of “Immune-checkpoint molecule”, PD-L1 showed significant associations in ccRCC (Figure 3B, p = 0.004 in the Miao et al., 2018 data (ICB)) while PD−L2 and CTLA−4 was significant in NSCLC (Figure 3D, Figures S12 and S13, Table S2e, p = 0.024, p = 0.028 in the Prat et al., 2017(NSCLC) dataset, respectively, Wilcoxon Rank Sum Test; p = 0.02, odds ratio = 2.9, [95%CI, 1.31–8.33], p = 0.04, odds ratio = 1.94, [95%CI, 1.07–3.88], respectively, Logistic regression model). The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.